Biogen's Alzheimer's drug loses subsidies in the US
The US government is limiting its coverage of Biogen's Alzheimer's drug, Aduhelm, due to the risk of adverse effects. Biogen's stock plummets.
by marketwire, translated by daniel pedersen
The US government will cut the subsidies available for Biogen's controversial Alzheimer's drug, Aduhelm, and the decision is being felt on the US stock post-market on Tuesday, reports Bloomberg News.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen's Alzheimer's drug blocked in Japan
For subscribers
Biogen slashes price of controversial Alzheimer's drug
For subscribers
